Cisplatin treatment induces a transient increase in tumorigenic potential associated with high interleukin-6 expression in head and neck squamous cell carcinoma

Molecular Cancer Therapeutics

Volumn 9, Issue 8, 2010, Pages 2430-2439

  Poth, Kim J ^a   Guminski, Alexander D ^b   Thomas, Gethin P ^a   Leo, Paul J ^a   Jabbar, Ibtissam A ^a   Saunders, Nicholas A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; INTERLEUKIN 6; TOCILIZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; SQUAMOUS CELL CARCINOMA;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CLONE CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-6; MICE; MICE, SCID; SIGNAL TRANSDUCTION; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955488364     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0258     Document Type: Article

References (29)

1. Dobrossy L. Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev 2005;24:9-17.
2. Chin D, Boyle GM, Porceddu S, et al. Head and neck cancer: past, present and future. Expert Rev Anticancer Ther 2006;6:1111-8. (Pubitemid 44203388)
3. Perez-Ordonez B, Beauchemin M, Jordan RC. Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol 2006;59:445-53.
4. Kim ES, Glisson BS. Treatment of metastatic head and neck cancer: chemotherapy and novel agents. Cancer Treat Res 2003;114:295-314.
5. Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 2007;4:156-71.
6. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-20.
7. Guminski AD, Harnett PR, deFazio A. Scientists and clinicians test their metal-back to the future with platinum compounds. Lancet Oncol 2002;3:312-8.
8. Kalish LH, Kwong RA, Cole IE, Gallagher RM, Sutherland RL, Musgrove EA. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2004;10:7764-74.
9. Dahler AL, Rickwood D, Guminski A, Teakle N, Saunders NA. Indole-3-carbinol - induced growth inhibition can be converted to a cytotoxic response in the presence of TPA+Ca(2+) in squamous cell carcinoma cell lines. FEBS Lett 2007;581:3839-47.
10. Gu W, Putral L, Hengst K, et al. Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther 2006;13:1023-32.
11. Rubinson DA, Dillon CP, Kwiatkowski AV, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003;33:401-6.
12. Endo-Munoz L, Dahler A, Teakle N, et al. E2F7 can regulate proliferation, differentiation, and apoptotic responses in human keratinocytes: implications for cutaneous squamous cell carcinoma formation. Cancer Res 2009;69:1800-8.
13. Barry SC, Harder B, Brzezinski M, Flint LY, Seppen J, Osborne WRA. Lentivirus vectors encoding both central polypurine tract and posttranscriptional regulatory element provide enhanced transduction and transgene expression. Human Gene Therapy 2001;12:1103-8.
14. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009;138:822-9.
15. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007;104:973-8. (Pubitemid 46154721)
16. Shinriki S, Jono H, Ota K, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res 2009;15:5426-34.
17. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-52.
18. De Schutter H, Landuyt W, Verbeken E, Goethals L, Hermans R, Nuyts S. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer 2005;5:42.
19. Duffy SA, Taylor JM, Terrell JE, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 2008;113:750-7.
20. Thomas GR, Chen Z, Leukinova E, Van Waes C, Wen J. Cytokines IL-1 α, IL-6, and GM-CSF constitutively secreted by oral squamous carcinoma induce down-regulation of CD80 costimulatory molecule expression: restoration by interferon γ. Cancer Immunol Immunother 2004;53:33-40.
21. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-κB, Lin28, Let-7 MicroRNA, IL6 links inflammation to cell transformation. Cell 2009;139:693-706.
22. Bernier J, Cooper JS. Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence? Oncologist 2005;10:215-24.
23. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-44.
24. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8.
25. Ferrari D, Codecà C, Fiore J, Luciani A, Foa P. A review on the treatment of relapsed/metastatic head and neck cancer. Expert Opin Pharmacother 2009;10:2625-32.
26. Treiber DK, Zhai X, Jantzen HM, Essigmann JM. Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Proc Natl Acad Sci U S A 1994;91:5672-6.
27. Brown SJ, Kellett PJ, Lippard SJ. Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science 1993;261:603-5.
28. Louie AY, Meade TJ. Metal complexes as enzyme inhibitors. Chem Rev 1999;99:2711-34.
29. Havelka AM, Berndtsson M, Olofsson MH, Shoshan MC, Linder S. Mechanisms of action of DNA-damaging anticancer drugs in treatment of carcinomas: is acute apoptosis an "off-target" effect? Mini Rev Med Chem 2007;7:1035-9.